High Efficiency of Antiviral CD4⁺ Killer T Cells

• Steven K. Hildemann,

  Affiliations University Clinic for Cardiology and Angiology I, University Heart Center, Freiburg-Bad Krozingen, Germany, Merck Research Laboratories/MSD Global Clinical Trial Operations, Haar, Germany

  ⨯
• Jens Eberlein,

  Affiliation Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado, United States of America

  ⨯
• Bennett Davenport,

  Affiliations Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado, United States of America, Integrated Department of Immunology, University of Colorado Denver and National Jewish Health, Denver, Colorado, United States of America, Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado, United States of America

  ⨯
• Tom T. Nguyen,

  Affiliations Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado, United States of America, Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado, United States of America

  ⨯
• Francisco Victorino,

  Affiliations Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado, United States of America, Integrated Department of Immunology, University of Colorado Denver and National Jewish Health, Denver, Colorado, United States of America

  ⨯
• Dirk Homann

  * E-mail: dirk.homann@ucdenver.edu

  Affiliations Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado, United States of America, Integrated Department of Immunology, University of Colorado Denver and National Jewish Health, Denver, Colorado, United States of America, Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado, United States of America

  ⨯